Altor BioScience

Biotech & Life Sciences · Miramar, United States · Founded 2002

Researches and develops immunotherapeutic agents for the treatment of cancer, viral infections and autoimmune diseases MoreLess

ImmunityBio, Inc. is a privately held immunotherapy company specializing in the development of advanced biological molecules to treat cancer and infectious diseases. The company operates in the biotechnology sector, focusing on creating therapies that harness the body's immune system to fight diseases. ImmunityBio serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The company’s business model revolves around research and development, clinical trials, and partnerships with other biotech firms to bring innovative treatments to market. Revenue is generated through licensing agreements, product sales, and collaborative research funding. ImmunityBio's portfolio includes albumin-linked chemotherapeutics, peptides, fusion proteins, cytokines, monoclonal antibodies, and both adenovirus and yeast vaccine therapies. The company is also actively involved in the development of a novel adenovirus COVID-19 vaccine, showcasing its commitment to addressing urgent global health challenges.

Keywords: immunotherapy, biological molecules, cancer treatment, infectious diseases, biotechnology, clinical trials, partnerships, COVID-19 vaccine, monoclonal antibodies, cytokines.

Valuation $0–100M

Headcount <100

Total funding $100–500M

Unlock exact values

Company overview

Altor BioScience company information

The essential company record, classifications and operating signals in one place.

Status: Acquired
Founded: 2002
Headquarters: Miramar, United States
Employees: 9
Open positions: None listed
Dealroom signal: 83.6

Website ↗LinkedIn ↗X ↗

client focusb2bsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorOncologysectorDrug DevelopmentsectorBiotech and PharmasectorHard TechsectorDT and LSsectorscience-based

Valuation & funding

Altor BioScience funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Jun 2017	$290M	—	NantCell \| Nantworks	—
GROWTH EQUITY VCOther financing	Mar 2017	$30M	—	Undisclosed	—
GROWTH EQUITY VCOther financing	Jul 2016	$20M	—	Undisclosed	—
GRANTOther financing	Oct 2015	$11M	—	National Institute of Neurological Disorders and Stroke · Bill & Melinda Gates Foundation · National Cancer Institute (NCI)	—
GROWTH EQUITY VCOther financing	Jun 2015	$11M	—	Undisclosed	—
GROWTH EQUITY VCOther financing	Mar 2013			Undisclosed	—
LATE VCOther financing	Jul 2012			Undisclosed	—
SERIES DOther financing	Jan 2011			Undisclosed	—
LATE VCOther financing	Jul 2010			Undisclosed	—
DEBTDebt	Mar 2010			Undisclosed	—

Showing 10 recorded eventsUnlock the complete deal history →

Growth signals

Altor BioScience website traffic

Latest recorded traffic for Altor BioScience is 0 monthly website visits. Altor BioScience's team grew 350% over the past year.

Latest monthly visits0 1-year team growth+350%

Monthly website visits45 observations · Apr 2016–Jun 2020

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Altor BioScience compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational	19	$60M	$240M
NTNEOGAP TherapeuticsImagine if cancer patients who lack efficient treatment options could be cured	Stockholms kommun, Sweden	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational
ASASYLIACompanion Diagnostics For Immunotherapy \| Asylia Diagnostics	Beerse, Belgium	Operational
PHPhilogenDevelop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders	Sovicille, Italy	Operational
IAImagene AIAI-based molecular testing for cancer	Tel Aviv-Yafo, Israel	Operational
EXExogeneBiotechnology company accelerating target and TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening	Oxford, United Kingdom	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Altor BioScience's talent

Book a demo to see the people

Team profiled 2 named & role-tagged

Founders /100 quality score

Key operators quality score

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Altor BioScience's cap table

Sourced from Dealroom's funding and investor records.

Seed 3 investors entered at this stage

National Institute of Neurological Disorders and Stroke

Bill & Melinda Gates Foundation

National Cancer Institute (NCI)

Series A 2 investors entered at this stage

Sanderling Ventures

Radius Ventures

Other known 2 additional known investors

NantCell | Nantworks

Techno Venture Management

Global footprint

Where Altor BioScience has talent and traffic

Workforce by country

🇺🇸 United States · Miramar HQ

Book a demo for the full country breakdown

In the news

Latest news about Altor BioScience

Recent press, funding announcements, and product moves mentioning Altor BioScience — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Altor BioScience

An AI-synthesized read of the highest-engagement posts about Altor BioScience on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Altor BioScience’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.